Back to results
US 2010/0136013 A1Published application
Cd55-interaction partners and the uses thereof
AssigneePercipio Biotherapeutics, Inc.
InventorGillian Lindy Durrant
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a binding member that binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to SCR1 and SCR2 of CD55 and neutralizing CD55 and making cancer cells susceptible to complement-mediated attack.
Claims11
1-25. (canceled)
A method of treating cancer comprising administration of a therapeutically effective amount of a naked binding member which specifically binds to SCR1 and SCR2 of CD55 to a mammal in need thereof.
Dependencies are inferred from the claim text.